Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. This activation leads to cell cycle block or apoptosis, depending on the nature of the DNA damage. In an attempt to enhance the effects of these agents, we inhibited ATM/ATR and Chk2, which are known upstream regulators of p53. The cancer cell lines A2780 and ARN8, bearing the wild-type p53 protein, were used to study changes in p53 activation and trans-activation. Our results suggest that the G(1)-checkpoint, normally activated by DNA damage, is functionally overcome by the action of kinase inhibitors that sensitize cells to apoptosis. Both inhibitors show these effects, albeit with variable intensity in different cell lines, which is promising for other studies and theoretically for use in clinical practice.

Department of Laboratory Medicine Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Oncological and Experimental Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc12025667

003      

CZ-PrNML

005      

20170411100104.0

007      

ta

008      

120817s2010 pl f 000 0#eng||

009      

AR

024    7_

$a 10.2478/s11658-010-0021-5 $2 doi

035    __

$a (PubMed)20526748

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a pl

100    1_

$a Hublarova, Pavla $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

245    10

$a Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases / $c Pavla Hublarova, Kristina Greplova, Jitka Holcakova, Borivoj Vojtesek,Roman Hrstka

520    9_

$a Cisplatin and doxorubicin are widely used anticancer drugs that cause DNA damage, which activates the ATM-Chk2-p53 pathway in cancer cells. This activation leads to cell cycle block or apoptosis, depending on the nature of the DNA damage. In an attempt to enhance the effects of these agents, we inhibited ATM/ATR and Chk2, which are known upstream regulators of p53. The cancer cell lines A2780 and ARN8, bearing the wild-type p53 protein, were used to study changes in p53 activation and trans-activation. Our results suggest that the G(1)-checkpoint, normally activated by DNA damage, is functionally overcome by the action of kinase inhibitors that sensitize cells to apoptosis. Both inhibitors show these effects, albeit with variable intensity in different cell lines, which is promising for other studies and theoretically for use in clinical practice.

650    _2

$a antitumorózní látky $x farmakologie $7 D000970

650    _2

$a apoptóza $7 D017209

650    _2

$a proteiny buněčného cyklu $x antagonisté a inhibitory $x metabolismus $7 D018797

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a cisplatina $x farmakologie $7 D002945

650    _2

$a poškození DNA $7 D004249

650    _2

$a DNA vazebné proteiny $x antagonisté a inhibitory $x metabolismus $7 D004268

650    _2

$a down regulace $7 D015536

650    _2

$a doxorubicin $x farmakologie $7 D004317

650    _2

$a průtoková cytometrie $7 D005434

650    _2

$a G0 fáze $7 D016192

650    _2

$a lidé $7 D006801

650    _2

$a inhibitory proteinkinas $x farmakologie $7 D047428

650    _2

$a protein-serin-threoninkinasy $x antagonisté a inhibitory $x metabolismus $7 D017346

650    _2

$a signální transdukce $7 D015398

650    _2

$a nádorový supresorový protein p53 $x metabolismus $7 D016159

650    _2

$a nádorové supresorové proteiny $x antagonisté a inhibitory $x metabolismus $7 D025521

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Greplova, Kristina $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic

700    1_

$a Holcakova, Jitka $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

700    1_

$a Vojtesek, Borivoj $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

700    1_

$a Hrstka, Roman $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

773    0_

$w MED00008291 $t Cellular & molecular biology letters $x 1689-1392 $g Roč. 15, č. 3 (2010), s. 473-484

856    41

$u https://pubmed.ncbi.nlm.nih.gov/20526748 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y m $z 0

990    __

$a 20120817 $b ABA008

991    __

$a 20170411100403 $b ABA008

999    __

$a ok $b bmc $g 947709 $s 783013

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2010 $b 15 $c 3 $d 473-484 $e 20100604 $i 1689-1392 $m Cellular and Molecular Biology Letters $n Cell. Mol. Biol. Lett. $x MED00008291

GRA    __

$a NS9812 $p MZ0

LZP    __

$a Pubmed-20120817/10/03